NYSE:HCP - HCP Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$34.78 As of 10/21/2021 01:00 AM ET

▼ -0.1 (-0.29%)

Get New HCP Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HCP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HCP

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for HCP in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $34.78.

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in HCP. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/23/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/8/2019	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$35.00 ➝ $38.00	Low
10/2/2019	Barclays	Boost Price Target	Overweight	$37.00 ➝ $39.00	Low
10/2/2019	KeyCorp	Boost Price Target	Overweight	$34.00 ➝ $37.00	Low
9/30/2019	Scotiabank	Set Price Target	Buy	$38.00	Medium
9/17/2019	Morgan Stanley	Boost Price Target	Equal Weight	$32.00 ➝ $35.00	High
9/10/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	$32.00 ➝ $35.00	High
9/10/2019	Argus	Upgrade	Hold ➝ Buy		High
9/3/2019	Barclays	Initiated Coverage	Overweight	$37.00	High
9/3/2019	Stifel Nicolaus	Boost Price Target	Buy	$34.00 ➝ $37.00	High
8/1/2019	Stifel Nicolaus	Boost Price Target	Buy	$32.00 ➝ $34.00	Medium
7/1/2019	KeyCorp	Boost Price Target	Overweight	$32.00 ➝ $34.00	Medium
6/13/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$35.00	Medium
3/28/2019	Morgan Stanley	Set Price Target	Hold	$32.00	Medium
2/13/2019	BMO Capital Markets	Reiterated Rating	Buy	$33.00	Low
1/9/2019	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$30.00 ➝ $33.00	Low
1/7/2019	Robert W. Baird	Upgrade	Neutral ➝ Outperform		Medium
12/10/2018	Scotiabank	Initiated Coverage	Outperform	$32.00	Medium
11/2/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform		Medium
11/1/2018	Cantor Fitzgerald	Boost Price Target	Overweight ➝ Overweight	$29.00 ➝ $30.00	Medium
10/31/2018	BMO Capital Markets	Reiterated Rating	Hold	$27.00	High
10/5/2018	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral		Low
9/27/2018	Cantor Fitzgerald	Upgrade	Neutral ➝ Overweight	$28.00 ➝ $29.00	High
9/17/2018	Bank of America	Boost Price Target	Buy	$27.50 ➝ $28.00	Medium
8/16/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$23.50 ➝ $25.00	Low
8/13/2018	Mizuho	Reiterated Rating	Buy	$29.00	Low
8/9/2018	Robert W. Baird	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $26.00	Low
8/7/2018	Cantor Fitzgerald	Initiated Coverage	Neutral	$28.00	Low
8/3/2018	Stifel Nicolaus	Set Price Target	Buy ➝ Buy	$27.00 ➝ $28.00	Low
7/24/2018	Capital One Financial	Initiated Coverage	Equal Weight	$27.50	Low
7/23/2018	Capital One Financial	Reiterated Rating	Equal Weight		Low
6/14/2018	Morgan Stanley	Lower Price Target	Equal Weight ➝ Equal Weight	$28.00 ➝ $23.50	Low
6/1/2018	Raymond James	Reiterated Rating	Market Perform		Low
6/1/2018	Evercore ISI	Downgrade	In-Line ➝ Underperform		Low
5/21/2018	Evercore ISI	Downgrade	In-Line ➝ Underperform	$23.02 ➝ $24.00	Low
5/21/2018	Raymond James	Downgrade	Outperform ➝ Market Perform		Low
5/3/2018	BMO Capital Markets	Reiterated Rating	Hold	$25.00	Low
3/20/2018	Wells Fargo & Company	Lower Price Target	Market Perform ➝ Market Perform	$31.00 ➝ $27.00	Low
3/8/2018	Bank of America	Upgrade	Neutral ➝ Buy	$22.63 ➝ $25.00	Low
2/23/2018	Royal Bank of Canada	Reiterated Rating	Hold	$27.00	Low
2/21/2018	UBS Group	Reiterated Rating	Sell ➝ Sell	$25.00 ➝ $21.00	Medium
2/15/2018	Robert W. Baird	Set Price Target	Hold	$24.00	Low
2/15/2018	Mizuho	Set Price Target	Buy	$26.00	Low
2/14/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $27.00	High
2/13/2018	Jefferies Financial Group	Reiterated Rating	Hold	$26.00	Medium
2/13/2018	BMO Capital Markets	Set Price Target	Hold	$25.00	Medium
1/15/2018	BMO Capital Markets	Set Price Target	Hold	$25.00	Low
1/5/2018	Robert W. Baird	Lower Price Target	Neutral ➝ Neutral	$29.00 ➝ $26.00	Medium
12/15/2017	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$29.00	Medium
12/14/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$29.00	Low
12/5/2017	Stifel Nicolaus	Upgrade	Hold ➝ Buy	$29.00	Low
11/7/2017	Stifel Nicolaus	Lower Price Target	Hold ➝ Hold	$30.00 ➝ $29.00	N/A
11/2/2017	Mizuho	Upgrade	Neutral ➝ Buy	$32.00	N/A
10/18/2017	BMO Capital Markets	Reiterated Rating	Hold	$28.00	N/A
10/17/2017	KeyCorp	Reiterated Rating	Hold		N/A
10/4/2017	Stifel Nicolaus	Reiterated Rating	Hold	$30.00	Low
10/2/2017	UBS Group	Downgrade	Neutral ➝ Sell	$30.00 ➝ $25.00	High
9/25/2017	Morgan Stanley	Lower Price Target	Equal Weight	$31.00 ➝ $29.00	Low
9/22/2017	Bank of America	Downgrade	Buy ➝ Neutral	$33.00 ➝ $31.00	High
9/17/2017	KeyCorp	Reiterated Rating	Hold		Low
9/6/2017	BMO Capital Markets	Reiterated Rating	Hold	$32.00	Low
8/22/2017	Stifel Nicolaus	Reiterated Rating	Hold	$30.00	Medium
7/25/2017	Jefferies Financial Group	Reiterated Rating	Hold	$33.00	Low
7/24/2017	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$35.00 ➝ $32.00	Medium
7/14/2017	Stifel Nicolaus	Reiterated Rating	Hold	$31.00	Medium
7/5/2017	Royal Bank of Canada	Reiterated Rating	Hold	$31.00	High
6/28/2017	Mizuho	Reiterated Rating	Neutral		Low
6/14/2017	Raymond James	Upgrade	Underperform ➝ Outperform	$35.00	Low
6/14/2017	UBS Group	Upgrade	Underperform ➝ Outperform		N/A
5/12/2017	Jefferies Financial Group	Reiterated Rating	Hold	$32.00	High
4/24/2017	Evercore ISI	Downgrade	In-Line ➝ Underperform		Medium
4/21/2017	Mitsubishi UFJ Financial Group	Initiated Coverage	Hold	$32.00	Low
4/11/2017	Mizuho	Downgrade	Buy ➝ Neutral	$34.00 ➝ $32.00	Low
4/3/2017	Bank of America	Upgrade	Neutral ➝ Buy	$33.25 ➝ $35.00	Low
3/27/2017	Evercore ISI	Upgrade	Underperform ➝ In-Line		Low
3/20/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight	$31.00	Low
3/10/2017	Robert W. Baird	Initiated Coverage	Neutral ➝ Neutral	$32.00	Low
3/3/2017	Evercore ISI	Downgrade	Hold ➝ Underperform		N/A
2/14/2017	BMO Capital Markets	Reiterated Rating	Hold	$30.00	N/A
2/14/2017	Barclays	Boost Price Target	Equal Weight	$32.00 ➝ $33.00	N/A
1/25/2017	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$29.00 ➝ $35.00	N/A
1/5/2017	Barclays	Reiterated Rating	Equal Weight	$32.00	N/A
1/3/2017	Royal Bank of Canada	Set Price Target	Hold	$30.00	N/A
12/23/2016	Mizuho	Reiterated Rating	Buy		N/A
12/13/2016	BMO Capital Markets	Upgrade	Underperform ➝ Market Perform	$29.00 ➝ $30.00	N/A
11/21/2016	Mizuho	Upgrade	Neutral ➝ Buy	$31.00 ➝ $32.00	N/A
11/4/2016	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$35.00 ➝ $30.00	N/A
11/2/2016	Stifel Nicolaus	Upgrade	Sell ➝ Hold	$33.00 ➝ $31.00	N/A
11/2/2016	Mizuho	Lower Price Target	Neutral	$37.00 ➝ $31.00	N/A
11/1/2016	BTIG Research	Reiterated Rating	Neutral		N/A
11/1/2016	BMO Capital Markets	Reiterated Rating	Sell	$33.00	N/A

(Data available from 10/23/2016 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/27/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/26/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/26/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/25/2021

1 very positive mentions
2 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

7/25/2021

1 very positive mentions
5 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/24/2021

3 very positive mentions
8 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/23/2021

3 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/23/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

HCP, Inc. is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.

Today's Range

Now: $34.78

$34.63

$34.97

50 Day Range

MA: $30.54

$28.42

$35.78

52 Week Range

Now: $34.78

$26.58

$37.93

Volume

1,750,341 shs

Average Volume

3,008,769 shs

Market Capitalization

$17.08 billion

P/E Ratio

19.11

Dividend Yield

4.14%

Beta

0.22

Frequently Asked Questions

What sell-side analysts currently cover shares of HCP?: The following sell-side analysts have issued stock ratings on HCP in the last year:
View the latest analyst ratings for HCP.
What is the current price target for HCP?: 0 Wall Street analysts have set twelve-month price targets for HCP in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for HCP in the next year.
View the latest price targets for HCP.
What is the current consensus analyst rating for HCP?: HCP currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HCP.
What other companies compete with HCP?: Other companies that are similar to HCP include American Tower, Public Storage, Welltower, Weyerhaeuser, Extra Space Storage, Ventas, Medical Properties Trust, CubeSmart, Life Storage, Omega Healthcare Investors, Rayonier, Healthcare Realty Trust, Ryman Hospitality Properties, EPR Properties and PotlatchDeltic.
How do I contact HCP's investor relations team?: HCP's physical mailing address is 1920 MAIN STREET SUITE 1200, IRVINE CA, 92614. The real estate investment trust's listed phone number is 949-407-0700 and its investor relations email address is [email protected] The official website for HCP is www.hcpi.com.

NYSE:HCP - HCP Stock Price Target and Predictions

Analyst Price Target for HCP

Current Consensus is N/A

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.64 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of HCP?

What is the current price target for HCP?

What is the current consensus analyst rating for HCP?

What other companies compete with HCP?

How do I contact HCP's investor relations team?